Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First human tests for kidney disease drug begin

NCT ID NCT07426380

Summary

This early-stage study aims to understand how a new drug called eloralintide behaves in people with severe kidney problems compared to healthy people. Researchers will give a single injection to 28 participants and track how much drug gets into their blood and how long it stays. The main goal is to gather safety information and see if kidney function affects how the body processes the drug.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Floridian Clinical Research, LLC

    RECRUITING

    Miami Lakes, Florida, 33016-1518, United States

    Contact Phone: •••-•••-••••

    Contact

  • Omega Research Orlando LLC

    RECRUITING

    Orlando, Florida, 32808, United States

    Contact Phone: •••-•••-••••

    Contact

Conditions

Explore the condition pages connected to this study.